Global Urinary Tract Cancer Treatment Market - 2022-2029

Global Urinary Tract Cancer Treatment Market - 2022-2029

Market Overview

The global urinary tract cancer treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

The most prevalent type of cancer detected in the urethra, bladder, and renal pelvis is urinary tract cancer. The gold standard procedure for diagnosing bladder cancer is a cystoscopy. In macroscopic hematuria, another method, computed tomography (CT) urography, is employed to obtain pictures of the upper tract. The exact cause of urinary tract cancer is unknown; however, long-term indwelling bladder catheters, smoking, chronic inflammation of the urinary system, and exposure to carcinogenic substances are all established risk factors.

Market Dynamics

The global urinary tract cancer treatment market is growing due to an increase in the prevalence of urinary tract cancer, the elderly population, and the number of bladder cancer research institutes.

Increasing prevalance of bladder cancer will drive the market growth

Increased prevalence of bladder cancer, increased funding from private and government organizations for the construction of research centers, increased elderly population, and increased R&D activities in the healthcare sector are all driving the worldwide urinary tract cancer market forward. Bladder cancer is the world's tenth most frequent cancer. According to the American Cancer Society, approximately 83,730 people in the United States will be diagnosed with bladder cancer in 2021. Furthermore, the bladder cancer research institutes, founded at the University of Birmingham in the United Kingdom, were sponsored with $1.18 million thanks to University investment and private donations. Furthermore, the rise in the geriatric population, which is more susceptible to bladder cancer, will propel the market forward throughout the projection period. Because the immune cells that combat cancer tissue in the bladder diminish with age, the elderly are more susceptible to urinary tract cancer. According to the American Society of Clinical Oncology (ASCO), over 90% of persons with bladder cancer will be over 55 in January 2021.

Furthermore, according to the American Cancer Society, bladder cancer can be caused by a combination of smoking and job exposure. For example, Merck, a leading global biopharmaceutical company, announced in August 2021 that Keytruda (pembrolizumab), used to treat Urothelial Carcinoma, has received FDA clearance in the United States. As a result, the market is expected to grow due to an increase in the number of approvals for the treatment of urinary tract cancer and an increase in sedentary lifestyles such as smoking and increased exposure to the chemical sector. Furthermore, there is a surge in the number of cancer research facilities and highly specialized urologists for cancer therapy.

Side effects caused by medications is likely to hamper the market growth

However, the market is stifled by the risks connected with the usage of medications used to treat urinary tract cancer.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic has negatively impacted the global urinary tract cancer marketAlmost all hospitals and cancer centers have reduced their outpatient capacity and conducted a triage to only select the patients most need a cystoscopy. This, in turn, caused cancellation and postponements of many non-essential surgical procedures across the world.

Segment Analysis

The bladder cancer segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

According to cancer type, the bladder cancer segment dominated the market in 2020 and is expected to maintain this trend during the forecast period, owing to increases in healthcare expenditure, advancements in available therapies, and increased bladder cancer prevalence.

According to the Cancer.Net 2022, bladder cancer affects an estimated 81,180 persons in the United States (61,700 men and 19,480 women). Smoking is responsible for 47% of all instances . Bladder cancer affected an estimated 573,278 persons worldwide in 2020. This illness is expected to kill 17,100 people in the United States this year (12,120 males and 4,980 women). Bladder cancer claimed the lives of an estimated 212,536 persons worldwide in 2020. Bladder cancer is the eighth most common cause of cancer death in men in the United States. However, after decades with no meaningful change, the fatality rate for bladder cancer reduced by nearly 2% from 2015 to 2019. Bladder cancer primarily affects the elderly. Bladder cancer affects about 90% of adults over the age of 55. Bladder cancer strikes persons at an average age of 73. These factors will boost this segment.

Geographical Analysis

North America region holds the largest market share of the global urinary tract cancer treatment market

North America accounted for a large share of the urinary tract cancer market in 2020 and is expected to maintain its dominance during the forecast period because of the rising prevalence of bladder cancer, increased healthcare expenditure, the presence of key players, availability of advanced cancer therapy, and advancement in R&D activities in the healthcare sector in the region

In addition, organic and inorganic strategies such as mergers and acquisitions and partnerships within key market players will strengthen their product portfolio in the studied market which will drive the market. Also, several product launches in the market will lead to lucrative growth of the market. For instance, in August 2021, BAVENCIO has been approved by the Food and Drug Administration (FDA) as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma. Furthermore, advancements in various treatment for urinary tract cancer from established key players, in the United States, are likely to drive the market growth in North America.

Competitive Landscape

The urinary tract cancer treatment market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Astellas Pharma Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, Endo International Plc, Exelixis Inc, GlaxoSmith Plc, Merck KGaA, Novartis AG, Pfizer Inc, Johnson & Johnson among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the urinary tract cancer treatment market globally. For instance, In September 2021, PADCEV® (enfortumab vedotin) is approved by Japan's MHLW for advanced urothelial cancer.

Eli Lilly and Company

Overview:

Eli Lilly and Corporation is an American pharmaceutical company with 18 countries and headquarters in Indianapolis, Indiana. Its goods are sold in more than 125 countries. Colonel Eli Lilly, a pharmaceutical chemist and American Civil War veteran, created the company in 1876 and named it after him.

Product Portfolio:

Cyramza: Cyramza (ramucirumab) is a single-agent recombinant human IgG1 monoclonal antibody intended to treat patients with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma who have progressed on or after fluoropyrimidine- or platinum-containing chemotherapy.

Why Purchase the Report?

Visualize the composition of the global urinary tract cancer treatment market segmentation by cancer type, treatment type, distribution channel, and region highlighting the key commercial assets and players.

Identify commercial opportunities in the global urinary tract cancer treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global urinary tract cancer treatment Market-level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global urinary tract cancer treatment market report would provide access to an approximately 40+ market data table, 45+ figures, and in the range of 180-200 (approximate) pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers